Activated zinc transporter ZIP7 as an indicator of anti-hormone resistance in breast cancer. Issue 9 (4th September 2019)

• Record Type: Journal Article
• Authors: Ziliotto, Silvia; Gee, Julia M. W.; Ellis, Ian O.; Green, Andrew R.; Finlay, Pauline; Gobbato, Anna; Taylor, Kathryn M.
• Is Part Of: Metallomics. Volume 11:Issue 9(2019)
• Page Start: 1579
• Page End: 1592
• Publication Date: 2019-09-04
• Subjects: Metals -- Physiological effect -- Periodicals; 572.51
• DOI: 10.1039/c9mt00136k
• Languages: English
• ISSNs: 1756-5901

Abstract

Abstract : Zinc transporter ZIP7 activates key downstream signalling pathways and is correlated with important clinicopathological parameters that are associated with endocrine resistance. Abstract : ZIP7, a member of the ZIP family of zinc importers, resides on the endoplasmic reticulum membrane and transports zinc from intracellular stores to the cytoplasm after activation by CK2 phosphorylation on two serine residues (S275 and S276). ZIP7 is known to be required for the growth of anti-hormone resistant breast cancer models, especially those with acquired tamoxifen resistance developed from MCF-7. Using our new pS 275 S 276 ZIP7 antibody which only recognises activated ZIP7 (pZIP7), we have demonstrated that the hyperactivation of ZIP7 is prevalent in tamoxifen-resistant breast cancer cells. This evidence suggests that pZIP7 might have potential as a biomarker of acquired resistance to such anti-hormones in breast cancer, a current unmet clinical need. In this regard, we have also developed a new immunohistochemical assay for pZIP7 which allowed pZIP7 to be tested on a small clinical series of breast cancer tissues confirming its prevalence in such tumours and relationship to a variety of clinicopathological parameters and biomarkers previously associated with endocrine resistant phenotypes, notably increased activated MAPK signalling, expression of ErbB2, CD71 and the proto-oncogene c-Fos, as well as with increased tumour grade.